Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial
Waijer SW, Vart P, Cherney DZ, Chertow GM, Jongs N, Langkilde AM, Mann JFE, Mosenzon O, Mcmurray JJ, Rossing P, Correa-Rotter R, Stefansson B, Toto RD, Wheeler DC, Heerspink HJL (2022)
Publication Type: Journal article
Publication year: 2022
Journal
DOI: 10.1007/s00125-022-05694-6
Abstract
Aims/hypothesis In the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) trial, dapagliflozin reduced the risks of progressive kidney disease, hospitalised heart failure or cardiovascular death, and death from all causes in patients with chronic kidney disease (CKD) with or without type 2 diabetes. Patients with more severe CKD are at higher risk of kidney failure, cardiovascular events and all-cause mortality. In this post hoc analysis, we assessed the efficacy and safety of dapagliflozin according to baseline Kidney Disease Improving Global Outcomes (KDIGO) risk categories.
Involved external institutions
University of Groningen / Rijksuniversiteit Groningen
Netherlands (NL)
University Health Network (UHN)
Canada (CA)
AstraZeneca UK Limited
United Kingdom (GB)
Stanford University
United States (USA) (US)
University of Glasgow
United Kingdom (GB)
Steno Diabetes Center
Denmark (DK)
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
Mexico (MX)
University of Texas Southwestern Medical Center (UT Southwestern)
United States (USA) (US)
University College London (UCL)
United Kingdom (GB)
KfH-Nierenzentrum / KfH Kidney Centre
Germany (DE)
Hadassah Medical Center / מרכז רפואי הדסה
Israel (IL)
Netherlands (NL)
University Health Network (UHN)
Canada (CA)
AstraZeneca UK Limited
United Kingdom (GB)
Stanford University
United States (USA) (US)
University of Glasgow
United Kingdom (GB)
Steno Diabetes Center
Denmark (DK)
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
Mexico (MX)
University of Texas Southwestern Medical Center (UT Southwestern)
United States (USA) (US)
University College London (UCL)
United Kingdom (GB)
KfH-Nierenzentrum / KfH Kidney Centre
Germany (DE)
Hadassah Medical Center / מרכז רפואי הדסה
Israel (IL)
How to cite
APA:
Waijer, S.W., Vart, P., Cherney, D.Z., Chertow, G.M., Jongs, N., Langkilde, A.M.,... Heerspink, H.J.L. (2022). Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial. Diabetologia. https://dx.doi.org/10.1007/s00125-022-05694-6
MLA:
Waijer, Simke W., et al. "Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial." Diabetologia (2022).
BibTeX: Download